Eagle Health Investments LP Buys Shares of 555,272 Scholar Rock Holding Corporation $SRRK

Eagle Health Investments LP bought a new position in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the 2nd quarter, Holdings Channel reports. The firm bought 555,272 shares of the company’s stock, valued at approximately $30,540,000. Scholar Rock makes up 5.1% of Eagle Health Investments LP’s investment portfolio, making the stock its 7th biggest holding.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC increased its stake in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after buying an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after acquiring an additional 5,831 shares during the period. Millennium Management LLC lifted its stake in Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after acquiring an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares in the last quarter. Finally, Strs Ohio bought a new position in Scholar Rock during the 1st quarter worth about $77,000. Institutional investors own 91.08% of the company’s stock.

Insider Activity

In related news, Director Jeffrey S. Flier sold 3,053 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director owned 27,856 shares of the company’s stock, valued at $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kristina Burow sold 3,053 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the sale, the director owned 114,657 shares of the company’s stock, valued at approximately $6,161,667.18. This trade represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,149 shares of company stock worth $923,108 over the last 90 days. 10.30% of the stock is currently owned by insiders.

Scholar Rock Price Performance

SRRK opened at $56.51 on Thursday. The firm has a market capitalization of $6.88 billion, a PE ratio of -16.38 and a beta of 0.69. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. The business’s 50-day moving average is $51.40 and its two-hundred day moving average is $48.34. Scholar Rock Holding Corporation has a 1 year low of $27.07 and a 1 year high of $58.49.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, meeting the consensus estimate of ($0.84). During the same quarter in the previous year, the business earned ($0.98) EPS. Research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SRRK has been the subject of several recent research reports. Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of Scholar Rock in a report on Monday, August 10th. Barclays increased their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Scholar Rock in a report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Friday, July 17th. Finally, BMO Capital Markets restated an “outperform” rating and set a $76.00 target price on shares of Scholar Rock in a report on Friday, August 7th. Four analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Scholar Rock presently has a consensus rating of “Buy” and an average price target of $57.71.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).